AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Mar 2 2021 AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference
- Feb 24 2021 AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
- Feb 16 2021 AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference
- Feb 9 2021 AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections